B+
Bull case
25%
Probability
Target price
$285.00
+34.0% vs current
NTRA
NateraCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$245.00
+15.2% vs current
B-
Bear case
25%
Probability
Target price
$185.00
-13.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.8
Score
AI commentary
As of this T+1 follow-up, the tone is cautiously positive but not euphoric. On May 7, 2026, NTRA closed at $216.00, down 1.74% on the day despite the beat-and-raise, which suggests high expectations and some digestion risk. By May 8, 2026, secondary analyst-note aggregators showed several price-target increases after the print, improving the revision signal, but breadth is still incomplete and this remains an early post-earnings read rather than a fully settled consensus shift. Headline volume is high because of earnings and multiple recent oncology/organ-health data releases; social coverage was not provided in the packet, so conviction stays tied to company filings, early analyst reaction, and monitoring against more direct MRD and genetic-testing peers.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-05-07catalystQ1 2026 beat-and-raise with first quarter above 1 million testsHigh impact
Natera reported Q1 2026 revenue of $696.6M, up 38.8% year over year, processed about 1.01M tests, delivered positive quarterly cash inflow, and raised 2026 revenue guidance to $2.74B-$2.82B from $2.62B-$2.70B midpoint prior; this is the clearest near-term support for the thesis and is directly confirmed by the May 7, 2026 earnings 8-K and attached release [#8-K-2026-05-07].
2026-09-30catalystSignatera and Fetal Focus adoption are supporting volume and mixHigh impact
Management tied strong Q1 performance to oncology and women's health adoption, with another record clinical oncology quarter, strong Signatera volume growth, and a successful Fetal Focus launch approaching an annualized run-rate of about 200K orders in the investor presentation furnished with the earnings 8-K [#8-K-2026-05-07].
2026-12-31eventJapan PMDA oncology milestone remains a dated 2026 watch itemHigh impact
The Q1 2026 investor presentation says PMDA approval for Signatera in Japan is expected in 2026 with commercial launch by year-end, creating a specific external milestone for additional colorectal-cancer MRD market expansion [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology